Jacobs Levy Equity Management
GNMX

Jacobs Levy Equity Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Jacobs Levy Equity Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,690
Closed -$45K – 1110
2018
Q3 		$45K Sell
36,690
-83,929
-70% -$93.8K ﹤0.01% 970
2018
Q2 		$134K Buy
120,619
+33,237
+38% +$50.5K ﹤0.01% 984
2018
Q1 		$176K Buy
+87,382
New +$164K ﹤0.01% 942
2016
Q3 		– Sell
-15,900
Closed -$88K – 1191
2016
Q2 		$88K Sell
15,900
-36,700
-70% -$193K ﹤0.01% 1098
2016
Q1 		$231K Buy
+52,600
New +$216K ﹤0.01% 941

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's GNMX Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 36,690 shares — an estimated $45K sold.

Jacobs Levy Equity Management first reported a position in GNMX in Q1 2016 and held it in 5 quarters. The position peaked at $231K in Q1 2016. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

  • Jacobs Levy Equity Management reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 36,690 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $45K.
  • Jacobs Levy Equity Management first reported a position in Aevi Genomic Medicine Inc in Q1 2016 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Aevi Genomic Medicine Inc position peaked at $231K in Q1 2016.
  • 38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.